Emerging drugs for primary Sjögren’s syndrome

References

• Brito-Zeron P, Baldini C, Bootsma H, et al. Sjogren syndrome. Nat Rev Dis Primers. 2016 Jul;7(2):16047. . PubMed PMID: 27383445; eng.
   PubMed Web of Science ®Google Scholar
• De Vita S, De Marchi G, Sacco S, et al. Preliminary classification of nonmalignant B cell proliferation in Sjogren’s syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach. Blood Cells Mol Dis. 2001 Jul-Aug;27(4):757–766. PubMed PMID: 11778660; eng.
   PubMed Web of Science ®Google Scholar
• Anderson LG, Talal N. The spectrum of benign to malignant lymphoproliferation in Sjogren’s syndrome. Clin Exp Immunol. 1972 Feb;10(2):199–221. PubMed PMID: 4625796; PubMed Central PMCID: PMCPMC1713180. eng
   PubMed Web of Science ®Google Scholar
• Tzioufas AG, Kapsogeorgou EK, Moutsopoulos HM. Pathogenesis of Sjogren’s syndrome: what we know and what we should learn. J Autoimmun. 2012 Aug;39(1–2):4–8. . PubMed PMID: 22326205; eng
   PubMed Web of Science ®Google Scholar
• Qin B, Wang J, Yang Z, et al. Epidemiology of primary Sjogren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015 Nov;74(11):1983–1989. PubMed PMID: 24938285; eng.
   PubMed Web of Science ®Google Scholar
• Vivino F, Bunya VY, Massaro-Giordano G, et al. Sjogren’s syndrome: an update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol. 2019 Apr 22. DOI:10.1016/j.clim.2019.04.009. [ PubMed PMID: 31022578; eng].
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Isola M, Baldini C, et al. Biomarkers of lymphoma in Sjogren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun. 2014 Jun;51:75–80. PubMed PMID: 24231556; eng.
   PubMed Web of Science ®Google Scholar
• Kroese FG, Abdulahad WH, Haacke E, et al. B-cell hyperactivity in primary Sjogren’s syndrome. Expert Rev Clin Immunol. 2014 Apr;10(4):483–499. PubMed PMID: 24564507; eng.
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Moutsopoulos HM. Sjogren syndrome. CMAJ. 2014 Oct 21;186(15):E579–86. . PubMed PMID: 24566651; PubMed Central PMCID: PMCPMC4203623. eng.
   PubMed Web of Science ®Google Scholar
• Cornec D, Devauchelle-Pensec V, Tobon GJ, et al. B cells in Sjogren’s syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun. 2012 Sep;39(3):161–167. PubMed PMID: 22749831; eng.
   PubMed Web of Science ®Google Scholar
• De Vita S, Boiocchi M, Sorrentino D, et al. Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjogren’s syndrome. Arthritis Rheumatism. 1997 Feb;40(2):318–331. PubMed PMID: 9041944; eng
   PubMedGoogle Scholar
• Tzioufas AG, Boumba DS, Skopouli FN, et al. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren’s syndrome. Arthritis Rheumatism. 1996 May;39(5):767–772. PubMed PMID: 8639173; eng
   PubMedGoogle Scholar
• Quartuccio L, Isola M, Baldini C, et al. Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjogren’s syndrome: results of a large multicentre study. Scand J Rheumatol. 2015;44(1):36–41. . PubMed PMID: 25268749; eng
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Baldini C, Priori R, et al. Cryoglobulinemia in Sjogren syndrome: a disease subset that links higher systemic disease activity, autoimmunity, and local B cell proliferation in mucosa-associated lymphoid tissue. J Rheumatol. 2017 Aug;44(8):1179–1183. PubMed PMID: 28507188; eng.
   PubMed Web of Science ®Google Scholar
• De Vita S, Soldano F, Isola M, et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis. 2011 Jul;70(7):1183–1190. PubMed PMID: 21571735; PubMed Central PMCID: PMCPMC3103668.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Isola M, Corazza L, et al. Validation of the classification criteria for cryoglobulinaemic vasculitis. Rheumatology (Oxford). 2014 Dec;53(12):2209–2213. PubMed PMID: 24994905.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Isola M, Corazza L, et al. Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S48–52. PubMed PMID: 22410397; eng
   PubMed Web of Science ®Google Scholar
• Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006 Jan 4;98(1):51–60. PubMed PMID: 16391371; eng.
   PubMedGoogle Scholar
• Voulgarelis M, Ziakas PD, Papageorgiou A, et al. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. Medicine (Baltimore). 2012 Jan;91(1):1–9. PubMed PMID: 22198497; eng.
   PubMed Web of Science ®Google Scholar
• Fragkioudaki S, Mavragani CP, Moutsopoulos HM. Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use. Medicine (Baltimore). 2016 Jun;95(25):e3766. . PubMed PMID: 27336863; PubMed Central PMCID: PMCPMC4998301. eng
   PubMed Web of Science ®Google Scholar
• Goules AV, Tzioufas AG. Lymphomagenesis in Sjogren’s syndrome: predictive biomarkers towards precision medicine. Autoimmun Rev. 2019 Feb;18(2):137–143. . PubMed PMID: 30572133; eng
   PubMed Web of Science ®Google Scholar
• Tobon GJ, Saraux A, Gottenberg JE, et al. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjogren’s syndrome. Arthritis Rheumatism. 2013 Dec;65(12):3218–3227. PubMed PMID: 23982978; eng.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Baldini C, Bartoloni E, et al. Anti-SSA/SSB-negative Sjogren’s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev. 2015 Nov;14(11):1019–1022. PubMed PMID: 26162302; eng.
   PubMed Web of Science ®Google Scholar
• Tzioufas AG, Goules AV. Limited efficacy of targeted treatments in Sjogren’s syndrome: why? Clin Exp Rheumatol. 2018 May-Jun;36(Suppl 112(3)):27–28. PubMed PMID: 29998826; eng
   PubMed Web of Science ®Google Scholar
• Pezoulas VC, Kourou KD, Kalatzis F, et al. Medical data quality assessment: on the development of an automated framework for medical data curation. Comput Biol Med. 2019 Apr;107:270–283. PubMed PMID: 30878889; eng.
   PubMed Web of Science ®Google Scholar
• Miyamoto ST, Valim V, Fisher BA. Health-related quality of life and costs in Sjogren’s syndrome. Rheumatology (Oxford). 2019 Feb 15. DOI:10.1093/rheumatology/key370. PubMed PMID: 30770918; eng.
   PubMedGoogle Scholar
• Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjogren syndrome: a systematic review. Jama. 2010 Jul 28;304(4):452–460. PubMed PMID: 20664046; eng.
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Afeltra A, Alunno A, et al. International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren’s syndrome)?: the unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017 Sep;16(9):911–924. PubMed PMID: 28705780; eng.
   PubMed Web of Science ®Google Scholar
• Carsons SE, Vivino FB, Parke A, et al. Treatment guidelines for rheumatologic manifestations of Sjogren’s syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken). 2017 Apr;69(4):517–527. PubMed PMID: 27390247; eng.
   PubMed Web of Science ®Google Scholar
• Sacchetti M, Mantelli F, Lambiase A, et al. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. Br J Ophthalmol. 2014 Aug;98(8):1016–1022. PubMed PMID: 24344232; eng.
   PubMed Web of Science ®Google Scholar
• Godin MR, Gupta PK. Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy. Clin Ophthalmol. 2017;11:951–957. . PubMed PMID: 28579745; PubMed Central PMCID: PMCPMC5449132. eng
   PubMed Web of Science ®Google Scholar
• Pan Q, Angelina A, Marrone M, et al. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2017 Feb;28(2):Cd009327. . PubMed PMID: 28245347; PubMed Central PMCID: PMCPMC5510593. eng.
   PubMed Web of Science ®Google Scholar
• Aragona P, Di Pietro R, Spinella R, et al. Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjogren’s syndrome. Br J Ophthalmol. 2006 Feb;90(2):166–170. PubMed PMID: 16424527; PubMed Central PMCID: PMCPMC1860166. eng.
   PubMed Web of Science ®Google Scholar
• Yamada H, Nakagawa Y, Wakamatsu E, et al. Efficacy prediction of cevimeline in patients with Sjogren’s syndrome. Clin Rheumatol. 2007 Aug;26(8):1320–1327. PubMed PMID: 17221146; eng.
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Ravaud P, Puechal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial. Jama. 2014 Jul 16;312(3):249–258. PubMed PMID: 25027140; eng.
   PubMed Web of Science ®Google Scholar
• De Vita S, De Marchi G, Sacco S, et al. Treatment of B-cell disorders of MALT in Sjögren’s syndrome with anti-CD20 monoclonal antibody. Proceedings of the 8th International Symposium on Sjögren’s syndrome Kanazawa, Japan; 2002. p. 51. P8–2.
   Google Scholar
• Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014 Feb 18;160(4):233–242. PubMed PMID: 24727841; eng.
   PubMed Web of Science ®Google Scholar
• Bowman SJ, Everett CC, O’Dwyer JL, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren’s syndrome. Arthritis Rheumatol (Hoboken). 2017 Jul;69(7):1440–1450. PubMed PMID: 28296257; eng.
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis. 2013 Jun;72(6):1026–1031. PubMed PMID: 23264337; eng.
   PubMed Web of Science ®Google Scholar
• Carubbi F, Cipriani P, Marrelli A, et al. Efficacy and safety of rituximab treatment in early primary Sjogren’s syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther. 2013 Oct 30;15(5):R172. PubMed PMID: 24286296; PubMed Central PMCID: PMCPMC3979092. eng.
   PubMed Web of Science ®Google Scholar
• St Clair EW, Levesque MC, Prak ET, et al. Rituximab therapy for primary Sjogren’s syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheumatism. 2013 Apr;65(4):1097–1106. PubMed PMID: 23334994; PubMed Central PMCID: PMCPMC3618621. eng.
   PubMed Web of Science ®Google Scholar
• Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatism. 2010 Apr;62(4):960–968. PubMed PMID: 20131246; eng.
   PubMed Web of Science ®Google Scholar
• Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren’s syndrome treated with rituximab. Ann Rheum Dis. 2012 Aug;71(8):1297–1302. PubMed PMID: 22258489; eng.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Fabris M, Salvin S, et al. Controversies on rituximab therapy in sjogren syndrome-associated lymphoproliferation. Int J Rheumatol. 2009;2009:424935. . PubMed PMID: 20148068; PubMed Central PMCID: PMCPMC2817502. eng
   PubMedGoogle Scholar
• De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheumatism. 2012 Mar;64(3):843–853. PubMed PMID: 22147661; eng.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Isola M, Masolini P, et al. Health-related quality of life in severe cryoglobulinaemic vasculitis and improvement after B-cell depleting therapy. Clin Exp Rheumatol. 2013 Jan-Feb;31(1 Suppl 75):S9–14. PubMed PMID: 23044040; eng
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Salvin S, et al. Sequential therapy with belimumab followed by rituximab in Sjogren’s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. Clin Exp Rheumatol. 2014 Jul-Aug;32(4):490–494. PubMed PMID: 24802131
   PubMed Web of Science ®Google Scholar
• Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999 Jun 7;189(11):1747–1756. PubMed PMID: 10359578; PubMed Central PMCID: PMCPMC2193079. eng
   PubMed Web of Science ®Google Scholar
• Ittah M, Miceli-Richard C, Eric Gottenberg J, et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren’s syndrome. Arthritis Res Ther. 2006;8(2):R51. . PubMed PMID: 16507175; PubMed Central PMCID: PMCPMC1526588. eng
   PubMed Web of Science ®Google Scholar
• Daridon C, Devauchelle V, Hutin P, et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren’s syndrome. Arthritis Rheumatism. 2007 Apr;56(4):1134–1144. PubMed PMID: 17393395; eng.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sjogren’s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford). 2013 Feb;52(2):276–281. PubMed PMID: 22879463; eng.
   PubMed Web of Science ®Google Scholar
• Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjogren’s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015 Mar;74(3):526–531. PubMed PMID: 24347569.
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Seror R, et al. Efficacy and safety of belimumab given for 12 months in primary Sjogren’s syndrome: the BELISS open-label phase II study. Rheumatology (Oxford). 2015 Dec;54(12):2249–2256. PubMed PMID: 26242856.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Salvin S, Corazza L, et al. Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjogren’s syndrome: follow-up after the end of the phase II open-label BELISS study. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):311–314. PubMed PMID: 26886154
   PubMed Web of Science ®Google Scholar
• Adler S, Korner M, Forger F, et al. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjogren’s syndrome: a pilot study. Arthritis Care Res (Hoboken). 2013 Nov;65(11):1862–1868. PubMed PMID: 23740889; eng.
   PubMed Web of Science ®Google Scholar
• Meiners PM, Vissink A, Kroese FG, et al. Abatacept treatment reduces disease activity in early primary Sjogren’s syndrome (open-label proof of concept ASAP study). Ann Rheum Dis. 2014 Jul;73(7):1393–1396. PubMed PMID: 24473674; eng.
   PubMed Web of Science ®Google Scholar
• Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren’s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren’s Syndrome (TRIPSS). Arthritis Rheumatism. 2004 Apr;50(4):1270–1276. PubMed PMID: 15077311; eng.
   PubMed Web of Science ®Google Scholar
• Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjogren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheumatism. 2004 Jul;50(7):2240–2245. PubMed PMID: 15248223; eng.
   PubMedGoogle Scholar
• Zandbelt MM, de Wilde P, van Damme P, et al. Etanercept in the treatment of patients with primary Sjogren’s syndrome: a pilot study. J Rheumatol. 2004 Jan;31(1):96–101. PubMed PMID: 14705226; eng
   PubMed Web of Science ®Google Scholar
• Mackay F, Groom JR, Tangye SG. An important role for B-cell activation factor and B cells in the pathogenesis of Sjogren’s syndrome. Curr Opin Rheumatol. 2007 Sep;19(5):406–413. . PubMed PMID: 17762603; eng
   PubMed Web of Science ®Google Scholar
• Batten M, Fletcher C, Ng LG, et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol. 2004 Jan 15;172(2):812–822. PubMed PMID: 14707051; eng
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferon-alpha pathway activation in patients with Sjogren’s syndrome treated with etanercept. Arthritis Rheumatism. 2007 Dec;56(12):3995–4004. PubMed PMID: 18050196; PubMed Central PMCID: PMCPMC2737264. eng.
   PubMedGoogle Scholar
• Norheim KB, Harboe E, Goransson LG, et al. Interleukin-1 inhibition and fatigue in primary Sjogren’s syndrome–a double blind, randomised clinical trial. PLoS One. 2012;7(1):e30123. . PubMed PMID: 22253903; PubMed Central PMCID: PMCPMC3254637
   PubMed Web of Science ®Google Scholar
• St Clair EW, Baer AN, Wei C, et al. Clinical efficacy and safety of baminercept, a lymphotoxin beta receptor fusion protein, in primary Sjogren’s syndrome: results from a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol (Hoboken). 2018 Sep;70(9):1470–1480. PubMed PMID: 29604186; PubMed Central PMCID: PMCPMC6115299. eng.
   PubMed Web of Science ®Google Scholar
• Pillemer SR, Brennan MT, Sankar V, et al. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjogren’s syndrome. Arthritis Rheumatism. 2004 Aug 15;51(4):601–604. PubMed PMID: 15334433; eng.
   PubMedGoogle Scholar
• Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren’s syndrome: an open-label phase I/II study. Arthritis Res Ther. 2006;8(4):R129. . PubMed PMID: 16859536; PubMed Central PMCID: PMCPMC1779377
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Dorner T, Bootsma H, et al. Efficacy of Epratuzumab, an Anti-CD22 monoclonal IgG antibody, in systemic lupus erythematosus patients with associated Sjogren’s syndrome: post hoc analyses from the EMBODY trials. Arthritis Rheumatol (Hoboken). 2018 May;70(5):763–773. PubMed PMID: 29381843; PubMed Central PMCID: PMCPMC5947119. eng.
   PubMed Web of Science ®Google Scholar
• Burge DJ, Eisenman J, Byrnes-Blake K, et al. Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-Fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study. Lupus. 2017 Jul;26(8):825–834. PubMed PMID: 27852935; eng.
   PubMed Web of Science ®Google Scholar
• Edman MC, Janga SR, Meng Z, et al. Increased Cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sjogren’s Syndrome patients. Sci Rep. 2018 Jul 23;8(1):11044. PubMed PMID: 30038391; PubMed Central PMCID: PMCPMC6056496. eng.
   PubMedGoogle Scholar
• Miao M, Hao Z, Guo Y, et al. Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjogren’s syndrome. Ann Rheum Dis. 2018 Dec;77(12):1838–1840. PubMed PMID: 29936436; eng.
   PubMed Web of Science ®Google Scholar
• Fonseca VR, Romao VC, Agua-Doce A, et al. The ratio of blood T follicular regulatory cells to T follicular helper cells marks ectopic lymphoid structure formation while activated follicular helper T cells indicate disease activity in primary Sjogren’s syndrome. Arthritis Rheumatol (Hoboken). 2018 May;70(5):774–784. PubMed PMID: 29361207; eng.
   PubMed Web of Science ®Google Scholar
• Ishikawa K, Ishikawa J, Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-kappaB and production of RANKL: its efficacy, radiographic changes, safety and predictors over two years’ treatment for Japanese rheumatoid arthritis patients. Mod Rheumatol. 2018 Jul 23:1–12. PubMed PMID: 29798702; eng. DOI:10.1080/14397595.2018.1481565.
   Web of Science ®Google Scholar
• Xu J, Wang D, Liu D, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome. Blood. 2012 Oct 11;120(15):3142–3151. PubMed PMID: 22927248; PubMed Central PMCID: PMCPMC3471521. eng.
   PubMed Web of Science ®Google Scholar
• Chen W, Yu Y, Ma J, et al. Mesenchymal stem cells in primary Sjogren’s syndrome: prospective and challenges. Stem Cells Int. 2018;2018:4357865. . PubMed PMID: 30305818; PubMed Central PMCID: PMCPMC6165618. eng
   PubMedGoogle Scholar
• De Vita S, Gandolfo S, Zandonella Callegher S, et al. The evaluation of disease activity in Sjogren’s syndrome based on the degree of MALT involvement: glandular swelling and cryoglobulinaemia compared to ESSDAI in a cohort study. Clin Exp Rheumatol. 2018 May-Jun;36(Suppl 112(3)):150–156. PubMed PMID: 30156548; eng
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Fabris M, Moretti M, et al. Resistance to rituximab therapy and local BAFF overexpression in Sjogren’s syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J. 2008;2:38–43. . PubMed PMID: 19088870; PubMed Central PMCID: PMCPMC2577948. eng
   PubMedGoogle Scholar
• Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005 Jan 15;174(2):817–826. PubMed PMID: 15634903; eng
   PubMed Web of Science ®Google Scholar
• Mahevas M, Michel M, Weill JC, et al. Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy. Front Immunol. 2013 Dec;27(4):494. . PubMed PMID: 24409184; PubMed Central PMCID: PMCPMC3873528. eng.
   PubMed Web of Science ®Google Scholar
• Rehnberg M, Amu S, Tarkowski A, et al. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11(4):R123. . PubMed PMID: 19686595; PubMed Central PMCID: PMCPMC2745807. eng
   PubMed Web of Science ®Google Scholar
• Teng YK, Levarht EW, Hashemi M, et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheumatism. 2007 Dec;56(12):3909–3918. PubMed PMID: 18050222; eng.
   PubMedGoogle Scholar
• Teng YK, Levarht EW, Toes RE, et al. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis. 2009 Jun;68(6):1011–1016. PubMed PMID: 18647852; eng.
   PubMed Web of Science ®Google Scholar
• Thurlings RM, Vos K, Wijbrandts CA, et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2008 Jul;67(7):917–925. PubMed PMID: 17965121; PubMed Central PMCID: PMCPMC2564787. eng.
   PubMed Web of Science ®Google Scholar
• Wild J, Schmiedel BJ, Maurer A, et al. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis. Leukemia. 2015 Aug;29(8):1676–1683. PubMed PMID: 25710310; eng.
   PubMed Web of Science ®Google Scholar
• Ahuja A, Shupe J, Dunn R, et al. Depletion of B cells in murine lupus: efficacy and resistance. J Immunol. 2007 Sep 1;179(5):3351–3361. PubMed PMID: 17709552; eng.
   PubMed Web of Science ®Google Scholar
• Banham GD, Flint SM, Torpey N, et al. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial. Lancet. 2018 Jun 30;391(10140):2619–2630. PubMed PMID: 29910042; eng.
   PubMed Web of Science ®Google Scholar
• Teng YKO, Bruce IN, Diamond B, et al. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open. 2019 Mar 20;9(3):e025687. PubMed PMID: 30898822; PubMed Central PMCID: PMCPMC6475247. eng.
   PubMed Web of Science ®Google Scholar
• Dorner T, Posch MG, Li Y, et al. Treatment of primary Sjogren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis. 2019 May;78(5):641–647. PubMed PMID: 30826774; eng.
   PubMed Web of Science ®Google Scholar
• Bombardieri M, Barone F, Humby F, et al. Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjogren’s syndrome. J Immunol. 2007 Oct 1;179(7):4929–4938. PubMed PMID: 17878393; eng
   PubMed Web of Science ®Google Scholar
• Le Pottier L, Devauchelle V, Fautrel A, et al. Ectopic germinal centers are rare in Sjogren’s syndrome salivary glands and do not exclude autoreactive B cells. J Immunol. 2009 Mar 15;182(6):3540–3547. PubMed PMID: 19265132; eng.
   PubMed Web of Science ®Google Scholar
• Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren’s syndrome. Ann Rheum Dis. 2011 Aug;70(8):1363–1368. PubMed PMID: 21715359; PubMed Central PMCID: PMCPMC3128323. eng.
   PubMed Web of Science ®Google Scholar
• Jobling K, Ng WF. CD40 as a therapeutic target in Sjogren’s syndrome. Expert Rev Clin Immunol. 2018 Jul;14(7):535–537. . PubMed PMID: 29874121; eng
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol Res. 2019 Mar 13;144:19–50. . PubMed PMID: 30877063; eng.
   PubMed Web of Science ®Google Scholar
• Lee J, Lee J, Kwok SK, et al. JAK-1 inhibition suppresses interferon-induced BAFF production in human salivary gland: potential therapeutic strategy for primary Sjogren’s syndrome. Arthritis Rheumatol (Hoboken). 2018 Dec;70(12):2057–2066. PubMed PMID: 29927095; eng.
   PubMed Web of Science ®Google Scholar
• Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM. The role of epithelial cells in the initiation and perpetuation of autoimmune lesions: lessons from Sjogren’s syndrome (autoimmune epithelitis). Lupus. 2006;15(5):255–261. . PubMed PMID: 16761498; eng
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Ramchandren R, Yacoub A, et al. Parsaclisib, a potent and highly selective PI3Kdelta inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019 Apr 18;133(16):1742–1752. PubMed PMID: 30803990; eng.
   PubMed Web of Science ®Google Scholar
• Zhang LW, Zhou PR, Wei P, et al. Expression of interleukin-17 in primary Sjogren’s syndrome and the correlation with disease severity: A systematic review and meta-analysis. Scand J Immunol. 2018 Apr;87(4):e12649. PubMed PMID: 29476557; eng.
   PubMed Web of Science ®Google Scholar
• Grosskreutz CL, Hockey HU, Serra D, et al. Dry eye signs and symptoms persist during systemic neutralization of IL-1beta by canakinumab or IL-17A by secukinumab. Cornea. 2015 Dec;34(12):1551–1556. PubMed PMID: 26418434; PubMed Central PMCID: PMCPMC4633966. eng.
   PubMed Web of Science ®Google Scholar
• Cao W, Bover L. Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells. Immunol Rev. 2010 Mar;234(1):163–176. . PubMed PMID: 20193018; PubMed Central PMCID: PMCPMC2919054. eng
   PubMedGoogle Scholar
• Hall JC, Baer AN, Shah AA, et al. Molecular subsetting of interferon pathways in Sjogren’s syndrome. Arthritis Rheumatol (Hoboken). 2015 Sep;67(9):2437–2446. PubMed PMID: 25988820; PubMed Central PMCID: PMCPMC4551661. eng.
   PubMed Web of Science ®Google Scholar
• Nezos A, Gravani F, Tassidou A, et al. Type I and II interferon signatures in Sjogren’s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren’s related lymphomagenesis. J Autoimmun. 2015 Sep;63:47–58. PubMed PMID: 26183766; PubMed Central PMCID: PMCPMC4564326. eng.
   PubMed Web of Science ®Google Scholar
• Imgenberg-Kreuz J, Sandling JK, Bjork A, et al. Transcription profiling of peripheral B cells in antibody-positive primary Sjogren’s syndrome reveals upregulated expression of CX3CR1 and a type I and type II interferon signature. Scand J Immunol. 2018 May;87(5):e12662. PubMed PMID: 29655283; eng.
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Mavragani CP, Nezos A, et al. Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjogren’s syndrome. Clin Exp Rheumatol. 2017 Jul-Aug;35(4):719–720. PubMed PMID: 28281461
   PubMed Web of Science ®Google Scholar
• Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol (Hoboken). 2017 Feb;69(2):376–386. PubMed PMID: 28130918; PubMed Central PMCID: PMCPMC5299497. eng.
   PubMed Web of Science ®Google Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Nov;75(11):1909–1916. PubMed PMID: 27009916; PubMed Central PMCID: PMCPMC5099191. eng.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70(11):1905–1913. PubMed PMID: 21798883; eng.
   PubMed Web of Science ®Google Scholar
• Cole S, Walsh A, Yin X, et al. Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2018 May 2;20(1):85. 10.1186/s13075-018-1578-z. PubMed PMID: 29720240; PubMed Central PMCID: PMCPMC5932888. eng
   PubMedGoogle Scholar
• Kapsogeorgou EK, Gourzi VC, Manoussakis MN, et al. Cellular microRNAs (miRNAs) and Sjogren’s syndrome: candidate regulators of autoimmune response and autoantigen expression. J Autoimmun. 2011 Sep;37(2):129–135. PubMed PMID: 21632209; eng.
   PubMed Web of Science ®Google Scholar
• Wang-Renault SF, Boudaoud S, Nocturne G, et al. Deregulation of microRNA expression in purified T and B lymphocytes from patients with primary Sjogren’s syndrome. Ann Rheum Dis. 2018 Jan;77(1):133–140. PubMed PMID: 28916716; PubMed Central PMCID: PMCPMC5754740. eng.
   PubMed Web of Science ®Google Scholar
• Kapsogeorgou EK, Papageorgiou A, Protogerou AD, et al. Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with Sjogren’s syndrome. Ann Rheum Dis. 2018 Aug;77(8):1200–1207. PubMed PMID: 29779010; eng.
   PubMed Web of Science ®Google Scholar
• Gambari R, Brognara E, Spandidos DA, et al. Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: nuew trends in the development of miRNA therapeutic strategies in oncology (Review). Int J Oncol. 2016 Jul;49(1):5–32. PubMed PMID: 27175518; PubMed Central PMCID: PMCPMC4902075. eng.
   PubMed Web of Science ®Google Scholar
• Tsilingiri K, Fornasa G, Rescigno M. Thymic stromal lymphopoietin: to cut a long story short. Cell Mol Gastroenterol Hepatol. 2017 Mar;3(2):174–182. . PubMed PMID: 28275684; PubMed Central PMCID: PMCPMC5331833. eng
   PubMed Web of Science ®Google Scholar
• Ferretti E, Hohaus S, Di Napoli A, et al. Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients. Oncotarget. 2017 Oct 17;8(49):85263–85275. PubMed PMID: 29156718; PubMed Central PMCID: PMCPMC5689608. eng.
   PubMedGoogle Scholar
• Astrakhan A, Omori M, Nguyen T, et al. Local increase in thymic stromal lymphopoietin induces systemic alterations in B cell development. Nat Immunol. 2007 May;8(5):522–531. PubMed PMID: 17401368; eng.
   PubMed Web of Science ®Google Scholar
• Demehri S, Liu Z, Lee J, et al. Notch-deficient skin induces a lethal systemic B-lymphoproliferative disorder by secreting TSLP, a sentinel for epidermal integrity. PLoS Biol. 2008 May 27;6(5):e123. PubMed PMID: 18507503; PubMed Central PMCID: PMCPMC2430908. eng.
   PubMed Web of Science ®Google Scholar
• Iseki M, Omori-Miyake M, Xu W, et al. Thymic stromal lymphopoietin (TSLP)-induced polyclonal B-cell activation and autoimmunity are mediated by CD4+ T cells and IL-4. Int Immunol. 2012 Mar;24(3):183–195. PubMed PMID: 22281511; PubMed Central PMCID: PMCPMC3284690. eng.
   PubMed Web of Science ®Google Scholar
• Sansonno D, Russi S, Sansonno S, et al. Thymic stromal lymphopoietin in hepatitis C virus-related cryoglobulinemic vasculitis: gene expression level and protein distribution. Arthritis Res Ther. 2015 Mar 15;17:62. 10.1186/s13075-015-0581-x. PubMed PMID: 25889007; PubMed Central PMCID: PMCPMC4391143. eng.
   PubMed Web of Science ®Google Scholar
• Gandolfo S, Fabro C, Bulfoni M, et al. Thymic Stromal Lymphopoietin (TSLP) expression is associated with lymphoproliferation and lymphoma in primary Sjögren’s syndrome [abstract]. Arthritis Rheumatol (Hoboken). 2017;69((suppl):10.
   Google Scholar
• Gandolfo S, Fabro C, Bulfoni M, et al. Serum levels of thymic stromal lymphopoietin: a possible novel biomarker in primary Sjögren’s Syndrome and related lymphoproliferation [abstract]. Arthritis Rheumatol (Hoboken). 2018;70(suppl):10.
   Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017 Sep 7;377(10):936–946. PubMed PMID: 28877011; eng.
   PubMed Web of Science ®Google Scholar
• Eberl G, Colonna M, Di Santo JP, et al. Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology. Science (New York, NY). 2015 May 22;348(6237):aaa6566. PubMed PMID: 25999512; PubMed Central PMCID: PMCPMC5658207. eng.
   Google Scholar
• Guggino G, Lin X, Rizzo A, et al. Interleukin-25 axis is involved in the pathogenesis of human primary and experimental murine Sjogren’s syndrome. Arthritis Rheumatol (Hoboken). 2018 Aug;70(8):1265–1275. PubMed PMID: 29569854; eng.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Giardina A, et al. The role of innate and lymphoid IL-22-producing cells in the immunopathology of primary Sjogren’s syndrome. Expert Rev Clin Immunol. 2014 Apr;10(4):533–541. PubMed PMID: 24490899; eng.
   PubMed Web of Science ®Google Scholar
• Vakrakou AG, Boiu S, Ziakas PD, et al. Systemic activation of NLRP3 inflammasome in patients with severe primary Sjogren’s syndrome fueled by inflammagenic DNA accumulations. J Autoimmun. 2018 Jul;91:23–33. PubMed PMID: 29551295; eng.
   PubMed Web of Science ®Google Scholar
• Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015 Mar;21(3):248–255. PubMed PMID: 25686105; PubMed Central PMCID: PMCPMC4392179. eng.
   PubMed Web of Science ®Google Scholar
• Murillo-Rodriguez E, Barciela Veras A, Barbosa Rocha N, et al. An overview of the clinical uses, pharmacology, and safety of modafinil. ACS Chem Neurosci. 2018 Feb 21;9(2):151–158. PubMed PMID: 29115823; eng.
   PubMed Web of Science ®Google Scholar
• Shangyan H, Kuiqing L, Yumin X, et al. Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue. Mult Scler Relat Disord. 2018 Jan;19:85–89. PubMed PMID: 29175676; eng.
   PubMed Web of Science ®Google Scholar
• Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010 Jun;69(6):1103–1109. PubMed PMID: 19561361; PubMed Central PMCID: PMCPMC2937022. eng.
   PubMed Web of Science ®Google Scholar